PITTSBURGH — Mylan N.V. has announced the U.S. launch of drospirenone and ethinyl estradiol tablets (3 mg/0.03 mg), an oral contraceptive.

Mylan said Tuesday that the product, a generic version of Yasmin tablets from Bayer, is available immediately and represents its 13th oral contraceptive launch in the United States.

Mylan’s partner Famy Care Ltd. received final approval from the Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for the generic product, which is indicated for use by women to prevent pregnancy.

Drospirenone and ethinyl estradiol tablets (3 mg/0.03 mg) had U.S. sales of about $137.6 million for the 12 months ended June 30, according to IMS Health figures cited by Mylan.